Intralipid

Soya Oil, the active ingredient in Intralipid, is a intravenous lipid emulsion presented as an intravenous emulsion for intravenous use. It provides calories and essential fatty acids for patients requiring parenteral nutrition, helping to prevent essential fatty acid deficiency and support caloric needs when oral intake is not possible.

GNH USA supplies Intralipid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Intralipid is used in clinical settings that require intravenous lipid supplementation for nutrition and metabolic support. - Parenteral nutrition: supplies calories and essential fatty acids to patients receiving total parenteral nutrition. - Essential fatty acid deficiency: corrects deficiency in patients unable to obtain adequate fatty acids orally. - Caloric supplementation in patients unable to eat orally: provides an energy source when oral intake is insufficient or contraindicated.

Intralipid may be associated with a range of infusion‑related reactions.

Common Side Effects: - Hypertriglyceridemia: elevated serum triglyceride levels during therapy. - Fever or chills: transient temperature rise during infusion. - Infusion site reactions: erythema, pain, or swelling at the catheter site. - Thrombocytopenia: mild reduction in platelet count. - Lipemia of plasma: milky appearance of blood samples.

Serious or Rare Side Effects: - Fat overload syndrome: severe metabolic disturbance from excessive lipid load. - Pulmonary embolism: rare embolic events related to lipid particles. - Anaphylactic reaction: severe allergic response, potentially life‑threatening. - Hepatic dysfunction: abnormal liver enzymes or steatosis with prolonged use. - Coagulopathy: impaired clotting due to dilutional effects.

When using Intralipid, clinicians should observe several safety measures. - Monitor triglyceride levels: check serum triglycerides regularly to avoid hypertriglyceridemia. - Assess liver function: adjust dosing in patients with hepatic impairment. - Use aseptic technique: prevent microbial contamination of the emulsion. - Evaluate for soy allergy: avoid in individuals with known hypersensitivity to soy components. - Adjust in sepsis: consider risk of fat overload in critically ill patients. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Intralipid can interact with other therapies that affect lipid metabolism or share infusion pathways.

Major Interactions (Avoid): - Concurrent lipid emulsions: cumulative fat load may precipitate fat overload syndrome. - Propofol infusion: both provide lipid calories, increasing risk of hypertriglyceridemia. - High‑dose heparin: may exacerbate triglyceride elevation.

Moderate Interactions (Monitor Closely): - Warfarin: lipid infusion can alter plasma protein binding, affecting anticoagulant levels. - Certain antibiotics (e.g., ceftriaxone): may precipitate when mixed with lipid emulsions. - Immunosuppressants (e.g., cyclosporine): monitor liver enzymes as both can affect hepatic metabolism.